Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 121-131

  Malhotra, Uma ^a,b   Berrey, M Michelle ^a   Huang, Yijian ^b   Markee, Janan ^b   Brown, Darin J ^a   Ap, Sophe ^a   Musey, Luwy ^a   Schacker, Timothy ^a,c   Corey, Lawrence ^a,b   McElrath, M Juliana ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MEMORY CELL; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; CANDIDA; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; FEMALE; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TETANUS TOXOID; VIRAL LOAD; ZIDOVUDINE;

EID: 0033966634     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315202     Document Type: Article

References (36)

1. 1. Koup R, Safrit J, Cao Y, et al. Temporal association of cellular immune response with the initíal control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
2. 2. Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M, CTL activity associated with control of viremia in primary HIV-1 infection. J Virol 1994;68: 6103-10.
3. 3. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Envelope cytotoxic T cell responses correlate with viral loud and disease progression in early HIV-1 infection. New Engl J Mod 1997;337:1267-74.
4. 4. Rinaldo C, Huang XL, Fan Z. et al. High levels of anti human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term non-progressors. J Virol 1995;69:5838-42.
5. 5. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995;11:903-7.
6. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4 [see comments]. Nature 1998;395:189-94.
7. + CTL response. J Exp Med 1996;183:2129-42.
8. 8. Shearer G, Payne S, Joseph L. Biddison W. Functional T lymphocyte immune deficiency in a population of homosexual men who do not exhibit symptoms of acquired immune deficiency syndrome. J Clin Invest 1984;74: 496-506.
9. 9. Lane H, Depper J, Greene W, Whalen G, Waldmann T, Fauci A. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. New Engl J Med 1985;313:79-84.
10. + T cell depletion occurs. J Clin Invest 1988;82:1908-14.
11. 11. Musey L, Krieger J, Hughes J, Schacker T, Corey L, McElrath MJ. Early and persistent HIV-1 specific T-helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999;180:278-84.
12. 12. Badley A, McElhinny J, Leibson P, Lynch D, Alderson M, Paya C. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
13. 13. Banda NK, Bernier J, Kurahara D, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176:1099-106.
14. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175: 331-40.
15. 15. Terai C, Kornbluth R, Pauza C, Richman D, Carson D. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991;87:1710-5.
16. 16. McCune JM. Thymic function in HIV-1 disease. Semin Immunol 1997;9: 397-404.
17. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies [see comments]. Nat Med 1997;3:533-40.
18. 18. Haynes BF, Hale LP, Weinhold KJ, et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 1999; 103:453-60.
19. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
20. 20. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
21. + T cell responses associated with control of viremia. Science 1997;287: 1447-50.
22. 22. Schacker T, Collier A, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64.
23. 23. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see comments]. New Engl J Med 1998;339:1261-8.
24. 24. Dewar R, Highbarger H, Sarmiento M, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
25. 25. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981;126:1614-9.
26. 26. McElrath MJ, Siliciano RF, Weinhold KJ. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-6.
27. 27. Ranki A, Suni J, Blazevic V, et al. T-cell recognition of HIV antigens in HIV-seroreverted persons [letter]. AIDS 1997;11:132-3.
28. 28. Schrier R, Wiley C, Spina C, McCutchan J, Grant I, the HNCRC Group. Pathogenic and protective correlates of T cell proliferation in AIDS. J Clin Invest 1996;98:731-40.
29. 29. Borkowsky W, Krasinski K, Moore T, Papaenvagelou V. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children. AIDS Res Hum Retroviruses 1990;6: 673-8.
30. +) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:8869-73.
31. 31. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [see comments]. Science 1997;278:1295-300.
32. + cytotoxic T-cell responses during chronic viral infection, J Virol 1994;68:8056-63.
33. 33. Tishon A, Lewicki H, Rall G, Von Herrath M, Oldstone MB. An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 1995;212:244-50.
34. 34. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic hone marrow by transfer of T-cell clones from the donor [see comments]. New Engl J Med 1995;333:1038-44.
35. 35. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med 1998; 187:1367-71.
36. 36. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.